A detailed history of Bank Of America Corp transactions in Xencor Inc stock. As of the latest transaction made, Bank Of America Corp holds 569,017 shares of XNCR stock, worth $12.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
569,017
Previous 493,315 15.35%
Holding current value
$12.1 Million
Previous $10.9 Million 1.34%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$18.21 - $24.5 $1.38 Million - $1.85 Million
75,702 Added 15.35%
569,017 $10.8 Million
Q1 2024

May 15, 2024

BUY
$18.65 - $26.52 $6.97 Million - $9.92 Million
373,943 Added 313.26%
493,315 $10.9 Million
Q4 2023

Feb 14, 2024

BUY
$16.53 - $21.42 $590,716 - $765,465
35,736 Added 42.73%
119,372 $2.53 Million
Q2 2023

Aug 14, 2023

SELL
$24.77 - $29.9 $3.23 Million - $3.9 Million
-130,424 Reduced 60.93%
83,636 $2.09 Million
Q1 2023

May 12, 2023

BUY
$25.95 - $36.95 $831,126 - $1.18 Million
32,028 Added 17.59%
214,060 $5.97 Million
Q4 2022

Feb 10, 2023

BUY
$24.79 - $30.86 $1.14 Million - $1.41 Million
45,800 Added 33.62%
182,032 $4.74 Million
Q3 2022

Nov 14, 2022

BUY
$24.62 - $32.44 $1.57 Million - $2.07 Million
63,676 Added 87.76%
136,232 $3.54 Million
Q2 2022

Aug 12, 2022

SELL
$19.74 - $29.01 $1.36 Million - $2 Million
-68,885 Reduced 48.7%
72,556 $1.99 Million
Q1 2022

May 16, 2022

BUY
$26.68 - $41.63 $1.29 Million - $2.02 Million
48,475 Added 52.14%
141,441 $3.77 Million
Q4 2021

Feb 08, 2022

BUY
$33.67 - $43.44 $1.55 Million - $2 Million
46,133 Added 98.51%
92,966 $3.73 Million
Q3 2021

Nov 15, 2021

BUY
$30.65 - $35.68 $332,705 - $387,306
10,855 Added 30.17%
46,833 $1.53 Million
Q2 2021

Sep 13, 2021

BUY
$34.33 - $44.68 $1.24 Million - $1.61 Million
35,978 New
35,978 $1.24 Million

Others Institutions Holding XNCR

About Xencor Inc


  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.27B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.